Will the two biosimilars sold by foreign companies be successful in the domestic market?

Lilly and MSD are expected to introduce biosimilars in the domestic market.

According to the industry concerned on the 18^th, Lilly and MSD have turned in approval applications for biosimilars of ‘Lantus(insulin glargine),’ a Sanofi’s basal insulin, and ‘Enbrel(etanercept),’ a Pfizer’s TNF-Alpha inhibitor(Developer: Amgen), respectively.

They are expected to be approved in the second half of t...